“What sets apixaban apart is its convenience and potential benefits over current treatments. With the study’s implications, this could signify an incredibly positive turning point for pediatric cardiology.”
INVESTIGATORS Clinical research at Riley Children’s Health is delivering novel insights into preventing thrombosis in children with congenital or acquired heart disease. SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease On the Prevention of Embolism) explores the safety and efficacy of apixaban—an alternative to standard treatment that offers hope in preventing blood clots in pediatric patients. READ about the study published in the Journal of the American College of Cardiology. >
Ronald M. Payne, MD, FAAP, FACC Cardiology Lead SAXOPHONE Investigator Professor of Pediatrics, IU School of Medicine > Connect with Dr. Payne on Doximity.
NEW TREATMENTS FOR FRIEDREICH’S ATAXIA > R EAD about Dr. Payne’s other major study that aims to uncover new potential treatments for the genetic disorder characterized by the loss of the frataxin protein in mitochondria.
Made with FlippingBook Digital Proposal Creator